medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-10-140-145medsovet-2545Research ArticleОбзорыReviewsКлинические и фармакоэкономические аспекты неоадъювантной терапии HER2-позитивного рака молочной железыClinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancerКосторовВ. А.KostorovV. A.СемиглазоваТ. Ю.SemiglazovaT. Yu.

Доктор медицинских наук

ПавлышА. В.PavlyshA. V.

Доктор медицинских наук

ГБУЗ «Ленинградский областной онкологический диспансер»РоссияState Budget Healthcare Institution «Leningrad regional oncology dispensary»Russian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава РоссииРоссияFederal State Budget Healthcare Institution «National Medical Research Oncology Center named after N.N. Petrov»Russian Federation201818072018010140145Copyright © Косторов В.А., Семиглазова Т.Ю., Павлыш А.В., 20182018Косторов В.А., Семиглазова Т.Ю., Павлыш А.В.Kostorov V.A., Semiglazova T.Y., Pavlysh A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2545

Достижение полного патоморфологического ответа на неоадъювантную лекарственную терапию HER-позитивного рака молочной железы (HER2+ РМЖ) позволяет за короткий срок значительно улучшить долгосрочный прогноз лечения, что свидетельствует о необходимости двойной анти-HER2-блокады при проведении неоадъювантных режимов терапии. Однако высокая стоимость таргетных препаратов требует оценки фармако-экономической целесообразности при выборе наиболее рационального подхода к лечению.

Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-blockade in neoadjuvant breast cancer therapy. However, the high cost of targeted drugs requires pharmacoecomomic assessments for choosing of the most optimal treatment course.

HER-позитивный рак молочной железынеоадъювантная терапиядвойная анти-HER2-блокадапертузумабтрастузумабHER-positive breast cancerneoadjuvant therapydouble anti-HER2-blockadepertuzumabtrastuzumabReferencesGiordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer, 2004 Jan 1, 100(1): 44-52.Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer, 2004 Jan 1, 100(1): 44-52.Feinstein AJ. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Aff, 2015 April, 34(4): 592-600.Feinstein AJ. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Aff, 2015 April, 34(4): 592-600.Dolgin E. Cancer’s cost conundrum. Nature, 2018. S29.Dolgin E. Cancer’s cost conundrum. Nature, 2018. S29.Piccart-Gebhart MJ. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med, 2005, 353: 1659-1672.Piccart-Gebhart MJ. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med, 2005, 353: 1659-1672.Gianni L et al Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010 Jan 30, 375(9712): 377-84.Gianni L et al Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010 Jan 30, 375(9712): 377-84.Untch M et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 2010 Apr 20, 28(12): 2024-31.Untch M et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 2010 Apr 20, 28(12): 2024-31.Untch M et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 2012 Feb, 13(2): 135-44.Untch M et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 2012 Feb, 13(2): 135-44.Prof Luca Gianni et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet. Oncology, 2016 June, 17(6): 791-800.Prof Luca Gianni et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet. Oncology, 2016 June, 17(6): 791-800.Kim M et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer M. Ann Oncol, 2013, 24(8): 1999-2004.Kim M et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer M. Ann Oncol, 2013, 24(8): 1999-2004.Schneeweiss A et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, 2013 September 1, 24(Issue 9): 2278-2284.Schneeweiss A et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, 2013 September 1, 24(Issue 9): 2278-2284.Attard L et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. Journal of Medical Economics, 2015, 18(3): 173-188.Attard L et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. Journal of Medical Economics, 2015, 18(3): 173-188.Ягудина Р.И., Куликов А.Ю., Метелкин И.А. Методология анализа «затраты – эффективность» при проведении фармакоэкономических исследований. Фармакоэкономика, 2012, 5(4).Yagudina RI, Kulikov AYu, Metelkin IA. The cost-effectiveness analysis methodology in pharmacoeconomic studies. Farmakoekonomika, 2012, 5 (4).Ягудина Р.И. и соавт. Оценка эффективности терапии и методы фармакоэкономических исследований. Фармакоэкономика, 2012, 5(4).Yagudina RI, et al. Evaluation of the effectiveness of therapy and methods of pharmacoeconomic research. Farmakoekonomika, 2012, 5 (4).Анализ «стоимости болезни»: виды, методология, особенности проведения в Российской Федерации Ягудина Р.И. и соавт. Фармакоэкономика Том 5, No 1, 2012Analysis of the “cost of illness”: types, methodology, features of the analysis in the Russian Federation Yagudina RI, et al. Farmakoekonomika, Volume 5, No 1, 2012Ягудина Р.И. и соавт. Особенности методологии фармакоэкономических исследований в условиях здравоохранения Российской Федерации (обзор публикаций за период с 1995 по 2007 гг.). Фармакоэкономика. 2009, 1: 3-6.Yagudina RI, et al. Features of the pharmacoeconomic research methodology in the context of healthcare of the Russian Federation (review of publications for the period from 1995 to 2007). Farmakoekonomika. 2009, 1: 3-6.Игнатьева В.И., Хачатрян Г.Р. Фармакоэкономический анализ двойной таргетной неоадъювантной терапии у пациенток с HER2 позитивным раком молочной железы. Медицинские технологии. Оценка и выбор, 2016, 1.Ignatieva VI, Khachatryan GR. Pharmacoeconomic analysis of dual target neoadjuvant therapy in patients with HER2 positive breast cancer. Meditsinskie Tehnologii. Otsenka i Vybor, 2016, 1.Ягудина Р.И., Куликов А.Ю, Нгуен Т.Т., Мусина Н.З. Фармакоэкономический анализ российского стандарта лечения рака молочной железы. Фармакоэкономика, 2009, 2(4).Yagudina RI, Kulikov AYu, Nguyen TT, Musina NZ. Pharmacoeconomic analysis of the Russian treatment standard for breast cancer. Farmakoekonomika, 2009, 2 (4).

The authors declare that there are no conflicts of interest present.